Phase 1 clinical study of eltrombopag, an oral, nonpeptide thrombopoietin receptor agonist. - Wikidata - wikimedia - TriplyDB

Phase 1 clinical study of eltrombopag, an oral, nonpeptide thrombopoietin receptor agonist.

Phase 1 clinical study of eltrombopag, an oral, nonpeptide thrombopoietin receptor agonist.

http://www.wikidata.org/entity/Q33374380

about

Thrombopoietin mimetics for patients with myelodysplastic syndromes TPO receptor agonist for chronic idiopathic thrombocytopenic purpura TPO receptor agonist for chronic idiopathic thrombocytopenic purpura Clinical indications for thrombopoietin and thrombopoietin-receptor agonists Current Management of Primary Immune Thrombocytopenia Eltrombopag in chronic hepatitis C Eltrombopag for the treatment of aplastic anemia: current perspectives Eltrombopag modulates reactive oxygen species and decreases acute myeloid leukemia cell survival New therapeutic options for adult chronic immune thrombocytopenic purpura: a brief review.New insights and therapeutics for immune-mediated thrombocytopenia.Historical review: megakaryopoiesis and thrombopoiesis Preclinical activity of eltrombopag (SB-497115), an oral, nonpeptide thrombopoietin receptor agonist.Review article: second-generation thrombopoietin agents for treatment of chronic idiopathic thrombocytopenic purpura in adults.Thrombocytopenia and hemostatic disorders in chronic graft versus host disease.Treatment of immune thrombocytopenic purpura: focus on eltrombopag.Effect of the nonpeptide thrombopoietin receptor agonist Eltrombopag on bone marrow cells from patients with acute myeloid leukemia and myelodysplastic syndrome Thrombopoietin and platelet production in chronic immune thrombocytopenia.New advances in the treatment of adult chronic immune thrombocytopenic purpura: role of thrombopoietin receptor-stimulating agents.Considerations in the management of hepatitis C virus-related thrombocytopenia with eltrombopag.Clinical pharmacokinetics, platelet response, and safety of eltrombopag at supratherapeutic doses of up to 200 mg once daily in healthy volunteers.Management of chronic immune thrombocytopenic purpura: targeting insufficient megakaryopoiesis as a novel therapeutic principle Treatment options for chronic refractory idiopathic thrombocytopenic purpura in adults: focus on romiplostim and eltrombopag.Biology and chemistry of thrombopoietic agents Effect of hepatic or renal impairment on eltrombopag pharmacokinetics.Eltrombopag--a novel approach for the treatment of chronic immune thrombocytopenic purpura: review and safety considerations.Dose escalation study of an anti-thrombocytopenic agent in patients with chemotherapy induced thrombocytopenia.Eltrombopag for the treatment of idiopathic thrombocytopenic purpura.Thrombopoietin receptor levels in tumor cell lines and primary tumors Current treatment options for primary immune thrombocytopenia.Infection-related transient loss of response and other early side effects in chronic ITP during treatment with thrombopoietin mimetics.Use of hematopoietic growth factor in the management of hematological side effects associated to antiviral treatment for HCV hepatitis Platelet activation and function during eltrombopag treatment in immune thrombocytopenia.Eltrombopag for the treatment of immune thrombocytopenia.Eltrombopag: a review of its use in treatment-refractory chronic primary immune thrombocytopenia.Spotlight on eltrombopag in treatment-refractory chronic primary immune thrombocytopenia.In vivo effects of eltrombopag on platelet function in immune thrombocytopenia: no evidence of platelet activation.Successful treatment with thrombopoietin receptor agonist in avoiding splenectomy for patients with chronic refractory immune thrombocytopenia Assessment of the pharmacokinetic interaction between eltrombopag and lopinavir-ritonavir in healthy adult subjects.Thrombopoietin receptor agonists in refractory immune thrombocytopenia: differential responses to eltrombopag and romiplostim: a case report and possible explanations.Eltrombopag inhibits the proliferation of leukemia cells via reduction of intracellular iron and induction of differentiation

P2860

Q24198060-46E5ED07-67CB-4D3C-87A6-56850B49E1E5 Q24235481-B5190427-306A-41AB-BC43-90077C64813E Q24241275-07666A4F-1506-4269-BB70-EC05C7513395 Q24601161-720A71A4-8A5D-4FA6-B503-395022F75710 Q26779408-3C0AD937-04C2-448A-9641-4E6143BEE29D Q26849334-0059CED1-FA63-4D45-B8E1-602EE43D2814 Q28071710-9461A4DA-ABF9-4FB0-AE25-D6036BF66FEB Q28546734-F64571BE-47FF-44FB-96DE-73FF6F7F04F4 Q33377221-2C706571-8DFB-45C6-9138-234C7AA98529 Q33377901-B8426041-C9D5-47C2-9555-576F699FA07B Q33378422-EF30751E-7A0A-4F3B-AF96-CB9B34DB5AEE Q33382190-D612DFCA-3B95-4DD0-895B-4F98F00944F8 Q33384996-AA93DD60-713F-47F1-8548-C1F4B5EF38F1 Q33385836-E2543FBC-A757-4126-977A-83FB183C26AB Q33385976-B3D2BE1A-A0BF-47EB-9828-62D8B5D8804A Q33385999-5B3FADB3-D430-4538-99A6-39F8DB805FDA Q33387153-56CC54F1-755B-4A45-80CB-7AA853419AD6 Q33387735-2F11F0BC-3AD7-498B-9B44-CB527124D7FF Q33387808-53D2B4D9-33B1-40A2-9AA9-00F837D3738A Q33389284-8AE4315C-5AF1-449B-B191-B6364B686178 Q33390001-7D0824C4-FAB1-4D79-BC0C-1BB1CD6C0B10 Q33390380-A086AD49-7209-4C19-806A-A56447B30045 Q33390625-A5854133-722F-4713-A958-68BBB0C42B6C Q33391009-E3327FB5-F35A-4852-9780-02C11A4596E5 Q33391229-27060693-7FDD-4E17-B250-E6C83CF60BDC Q33392349-5484D17F-B532-4BCA-B40B-617A64ACD136 Q33392852-E0636FCE-A18F-4A7A-ADAA-F1DE744A34C9 Q33394117-AC45B385-E65A-4B32-9221-E92408ACD65F Q33394149-63B2026C-C9D3-4BEF-BFC5-C0983FE634EC Q33394296-701F8DDC-E60B-4B38-97FB-00BB3A1F01A1 Q33394544-E2F16BAE-6D8D-4B99-B904-2DF7FCFEFA5C Q33395231-48F9D148-8302-445C-B770-B66F1CFD242E Q33395776-9741A46A-CCDA-4CC1-8ABB-AFB7B67D25AB Q33396286-813A6F8E-9FC6-4F3C-83BC-D48AFF49CFAC Q33397968-98F52719-238A-4FB0-9E73-1CF0A94D4419 Q33399437-71AE2FC4-32C1-43D1-BCD6-96D1C073BF7F Q33399821-389FC75F-BC07-41F2-8DBE-03ADC93AA0DC Q33400092-C6415D06-90B3-4543-8201-F86008F7C79F Q33401211-575CED1A-9DAF-4385-AF22-DC3A88194A75 Q33401421-3C7A37B4-191F-4F67-93A4-EAF5DAF8D768

P2860

Phase 1 clinical study of eltrombopag, an oral, nonpeptide thrombopoietin receptor agonist.

http://www.wikidata.org/entity/Q33374380

description

2007 nî lūn-bûn

@nan

2007 թուականի Փետրուարին հրատարակուած գիտական յօդուած

@hyw

2007 թվականի փետրվարին հրատարակված գիտական հոդված

@hy

2007年の論文

@ja

2007年論文

@yue

2007年論文

@zh-hant

2007年論文

@zh-hk

2007年論文

@zh-mo

2007年論文

@zh-tw

2007年论文

@wuu

name

Phase 1 clinical study of eltr ...... rombopoietin receptor agonist.

@ast

Phase 1 clinical study of eltr ...... rombopoietin receptor agonist.

@en

type

label

Phase 1 clinical study of eltr ...... rombopoietin receptor agonist.

@ast

Phase 1 clinical study of eltr ...... rombopoietin receptor agonist.

@en

prefLabel

Phase 1 clinical study of eltr ...... rombopoietin receptor agonist.

@ast

Phase 1 clinical study of eltr ...... rombopoietin receptor agonist.

@en

P1433

Q33374380-B897FD0B-200A-4BAB-8753-99B2D11B8E31

P1476

Q33374380-68604922-E5A2-4D81-846C-3DEFF4502479

P2093

Q33374380-1ACC6597-0697-4075-961C-6E47E073AE43

Q33374380-24D996D9-2530-4845-BC42-E11E3061EE30

Q33374380-60B0DDED-4953-47C4-B064-8AF80D4C7144

Q33374380-96BC5D55-A4D0-4283-AC7D-A3FDF744DA59

Q33374380-A2C73D2F-7E9D-4851-AF02-845078996141

Q33374380-F15D7420-ADCA-41BE-BE5B-709DD9E66367

Q33374380-FB1F6EBE-29FC-48C3-B945-1BF025860EA3

P304

Q33374380-D2A82F2D-519E-418A-B829-6D84FA7F2686

P31

Q33374380-84D085BA-A1D0-48AF-9172-199F3186448E

P356

Q33374380-2A7EF5F1-DA9C-47DB-91C5-3CD48A4AE994

P407

Q33374380-B366F0FB-C60B-4B03-AE4C-33B55AAA22BD

P433

Q33374380-C1672459-95CC-402F-BD91-592052FFF756

P478

Q33374380-1EE8ACFC-7680-47C3-87AA-1F95F1369182

P577

Q33374380-6976E82C-CE50-4FF8-A735-F1EDDA51BAAA

P5875

Q33374380-082FF412-7D38-44C9-A8D7-35E3582D2538

P698

Q33374380-6272515E-ED77-40F9-90E4-80F18ABE997B

P356

BLOOD-2006-11-057968

P1433

P1476

Phase 1 clinical study of eltr ...... rombopoietin receptor agonist.

@en

P2093

Connie L Erickson-Miller

http://www.w3.org/2001/XMLSchema#string

Daphne Williams

http://www.w3.org/2001/XMLSchema#string

David Collins

http://www.w3.org/2001/XMLSchema#string

Joanne Uhl

http://www.w3.org/2001/XMLSchema#string

Julian M Jenkins

http://www.w3.org/2001/XMLSchema#string

Valerie Kitchen

http://www.w3.org/2001/XMLSchema#string

Yanli Deng

http://www.w3.org/2001/XMLSchema#string

P304

4739-4741

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1182/BLOOD-2006-11-057968

http://www.w3.org/2001/XMLSchema#string

P407

P433

11

http://www.w3.org/2001/XMLSchema#string

P478

109

http://www.w3.org/2001/XMLSchema#string

P577

2007-02-27T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

6479938

http://www.w3.org/2001/XMLSchema#string

P698

17327409

http://www.w3.org/2001/XMLSchema#string